Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Coronary Artery Disease

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MCA.0000000000000031PMID 24145765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rivaroxaban in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis

  2012cited by this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

  2011cited by this paper
• New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

  2009cited by this paper
• Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial

  2009cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

  2009cited by this paper
• Bmc Medical Research Methodology Open Access Estimating Required Information Size by Quantifying Diversity in Random-effects Model Meta-analyses

  2009cited by this paper
• Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  2008cited by this paper
• Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.

  2008cited by this paper
• Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.

  2008cited by this paper
• Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  2008cited by this paper
• Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.

  2007cited by this paper
• Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

  2005cited by this paper
• Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

  2005cited by this paper
• APPLYING THE LAW OF ITERATED LOGARITHM TO CUMULATIVE META-ANALYSIS OF A CONTINUOUS ENDPOINT

  2003cited by this paper
• Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina.

  2002cited by this paper
• Warfarin, aspirin, or both after myocardial infarction.

  2002cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ☆

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study

  2002cited by this paper
• Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial

  2002cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

  1998cited by this paper
• Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.

  1997cited by this paper
• Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction

  1994cited by this paper

• The role of rivaroxaban in the management of coronary artery disease: an overview of five landmark clinical trials.

  2025cites this paper
• Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome

  2023influential citation
• Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.

  2023cites this paper
• Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.

  2023cites this paper
• Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation

  2023influential citation
• [Modern issues of improving the prognosis in patients with atrial fibrillation after ischemic stroke].

  2022cites this paper
• [Atrial fibrillation and cognitive impairment: features of the relationship, developmental and prevention mechanisms].

  2022cites this paper
• Do non-vitamin K antagonist oral anticoagulants increase the risk of myocardial infarction?

  2022cites this paper
• Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.

  2022cites this paper
• Preoperative Atrial Fibrillation and Cardiovascular Outcomes After Noncardiac Surgery.

  2022cites this paper
• Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

  2022cites this paper
• Пожилой пациент с фибрилляцией предсердий и коронарные риски

  2021cites this paper
• The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

  2021cites this paper
• Mejorar la prevención de la trombosis y las complicaciones cardiovasculares durante la pandemia de COVID-19

  2021cites this paper
• [Atrial fibrillation in old age: risk management and features of the use of direct oral anticoagulants].

  2021cites this paper
• Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy

  2021cites this paper
• [Management of patients with atrial fibrillation and minor bleeding during therapy with direct oral anti-coagulants].

  2021cites this paper
• Problems of selecting an anticoagulant for secondary stroke prevention in patients with atrial fibrillation

  2021cites this paper
• Elderly patient with atrial fibrillation and coronary risks

  2021cites this paper
• Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis

  2021cites this paper
• Recomendaciones de expertos en la mejora de la prevención efectiva del ictus isquémico en la fibrilación auricular no valvular: papel del rivaroxabán

  2020cites this paper
• [Risk of Coronary Events in Atrial Fibrillation].

  2020cites this paper
• Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

  2020cites this paper
• Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán

  2020cites this paper
• Análisis de la protección global del paciente con fibrilación auricular con rivaroxabán

  2020cites this paper
• Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus

  2020cites this paper
• Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.

  2020cites this paper
• A patient with atrial fibrillation and comorbidities in clinical practice

  2020cites this paper
• An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants?

  2020cites this paper
• Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review

  2019cites this paper
• [Rivaroxaban in prevention of stroke in elderly patients with non-valvular atrial fibrillation].

  2019cites this paper
• Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1

  2019cites this paper
• Non‐vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?

  2019cites this paper
• Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review

  2019cites this paper
• Dabigatran versus vitamin k antagonist: an observational across‐cohort comparison in acute coronary syndrome patients with atrial fibrillation

  2018cites this paper
• Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.

  2018cites this paper
• Rivaroxaban: searching the integral vascular protection

  2018cites this paper
• Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies.

  2018cites this paper
• Sex‐Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation

  2017cites this paper
• Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation

  2017cites this paper
• Safety of non-vitamin K antagonist oral anticoagulants - coronary risks

  2016cites this paper
• Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.

  2016cites this paper
• The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use

  2016cites this paper
• The new oral anticoagulants: Reasonable alternatives to warfarin

  2015cites this paper
• Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials

  2015cites this paper
• Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence

  2014cites this paper
• [Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].

  2014cites this paper
• Когда и как применять дабигатран при фибрилляции предсердий

  2012cites this paper